Skip to main content

Table 3 Univariate and multivariate analysis of prognostic factors for progression-free survival and overall survival (n = 48)

From: Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer

Variable No. of patients Univariate analysis Multivariate analysis
2-y Survival rate (%) PFS OS
PFS p-value OS p-value HR (95% CI) p-value HR (95% CI) p-value
Age
  ≥ 50 years 29 35.6   36.8   0.52 (0.27–1.01) 0.053   
  < 50 years 19 10.5 0.034 26.3 0.096 Reference    
Size of the cervical tumor
  ≥ 4-cm 39 21.7   28.2      
  < 4-cm 9 38.1 0.338 51.9 0.207     
Histological subtype
 Squamous cell carcinoma 39 28.0   38.5      
 Non-squamous cell carcinoma 9 11.1 0.064 0 0.002     
ECOG performance status score
 0 33 27.6   35.2      
 1–2 15 16.7 0.466 26.7 0.654     
Pre-treatment Hb (g/dL)
  > 10 37 23.1   29.7      
  ≤ 10 11 27.7 0.622 41.6 0.385     
Pre-treatment WBC(10^9 /L)
  > 10 8 25.0   25.0      
  ≤ 10 40 23.8 0.415 34.0 0.330     
Oligometastasis
 Yes 21 37.5   52.4      
 No 27 12.2 0.037 16.3 0.042     
Bone metastasis
 Yes 28 23.1   33.9      
 No 20 25.5 0.716 30 0.662     
Number of organ metastasis
 Single 37 26.7   37.8      
 Multiple 11 18.2 0.371 12.1 0.160     
Lung metastasis
 Yes 14 8.2   14.3      
 No 34 30.3 0.116 40 0.115     
Liver metastasis
 Yes 10 24.3   25      
 No 38 26.7 0.805 34.2 0.656     
Distant lymph node metastasis
 Yes 20 16   16.9      
 No 28 29.5 0.203 42.9 0.063     
Treatment mode
 Group A 36 30.4   38.9   0.40 (0.19–0.84) 0.015 0.32 (0.15–0.67) 0.003
 Group B 12 0 0.008 12.5 0.002 Reference   Reference  
  1. ECOG Eastern Cooperative Oncology Group, CI confidence interval, HR hazard ratio, OS overall survival, PFS progression-free survival, Hb hemoglobin, WBC white blood cell count